Solid Biosciences Inc.

NasdaqGS SLDB

Solid Biosciences Inc. Operating Income Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -2,366.91%

Solid Biosciences Inc. Operating Income Margin is -2,366.91% for the Trailing 12 Months (TTM) ending September 30, 2024, a -64.37% change year over year. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.

Solid Biosciences Inc. Operating Income Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was -1,439.99%, a -78.90% change year over year.
Solid Biosciences Inc. Operating Income Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was -804.93%, a -1,068.28% change year over year.
Solid Biosciences Inc. Operating Income Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -68.90%.

Key data

Date	Operating Income Margin	EBT Margin	Net Income Margin	EBITDA Margin

NasdaqGS: SLDB

Solid Biosciences Inc.

CEO	Mr. Alexander G. Cumbo
IPO Date	Jan. 26, 2018
Location	United States
Headquarters	141 Portland Street
Employees	88
Sector	Healthcare
Industries Biotechnology

Description

Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Key trends

Past 5 years